VKTX
Viking Therapeutics, Inc.
September 23, 2026 · after-hours
- Rarity
- 2.36
- Peak move
- −15.43%
- Float cap
- $4.6B
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. It is developing VK2735 for patients with obesity and related metabolic conditions, VK2809 for NASH/MASH, and VK0214 for X-linked adrenoleukodystrophy, while also advancing a preclinical dual amylin and calcitonin receptor agonist program for obesity.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
14 events · 3 from SEC or newswire · 3 timed with the move- Key eventTimed with the move
equity_offeringViking Therapeutics announced proposed concurrent public offerings of common stock and convertible senior notes, subject to market conditions.
- Timed with the move
equity_offeringViking Therapeutics announced a proposed public offering of $200 million of common stock with a 30-day underwriter option for an additional $30 million, with Morgan Stanley and J.P. Morgan as joint book-running managers and proceeds to fund VK2735 and VK3019 development.
- Timed with the move
convertible_offeringViking Therapeutics announced a proposed offering of $200 million of convertible senior notes due October 15, 2032, senior unsecured with a 30-day $30 million over-allotment option and terms to be set at pricing, alongside its equity raise.
convertible_offeringViking Therapeutics filed a preliminary prospectus supplement for a debt offering, takedown #2 of 2 under its shelf registration, with Morgan Stanley and J.P. Morgan as underwriters and price and size not yet set.
SEC424B5 0001193125-26-399628convertible_offeringViking Therapeutics filed a preliminary prospectus supplement for a debt offering, takedown #1 of 2 under its shelf registration, with Morgan Stanley and J.P. Morgan as underwriters and price and size not yet set.
SEC424B5 0001193125-26-399627analyst_ratingTruist analyst Gregory Renza raised his price target on Viking Therapeutics to $87 from $83 and maintained a Buy rating, calling the VK2735 maintenance data a "best-case scenario" for depth of weight loss, retention and tolerability.
equity_offeringViking Therapeutics priced an upsized $500 million concurrent offering of 7,857,143 common shares and convertible senior notes.
large_option_expiryMarketBeat reported investors purchased a large volume of call options on Viking Therapeutics.
executive_remarkOn Viking's VK2735 maintenance-data call, obesity specialist Louis Aronne said going from a mono-agonist to a dual agonist would be expected to produce greater weight loss and that fewer shots could help patients maintain weight loss, while CEO Brian Lian said Viking has asked the FDA about dose selection and frequency without settling on regimens.
analyst_ratingMorgan Stanley reiterated a Buy rating on Viking Therapeutics with a $95.00 price target, and Goldman Sachs stayed neutral while reiterating a $38 price target, saying the VK2735 results were encouraging but anticipated.
- Key event
peer_disclosureRoche/Genentech reported positive Phase II results for its once-weekly dual GLP-1/GIP agonist enicepatide (CT-388), acquired with Carmot, showing 15.5% weight loss over 48 weeks and 90% of patients reaching A1C below 6.5% in adults with type 2 diabetes who were overweight or obese.
- Key event
clinical_readoutViking Therapeutics reported topline results from its maintenance dosing study of GLP-1/GIP agonist VK2735, showing 22% placebo-adjusted weight loss at Week 33 with weekly 17.5 mg dosing, no plateau, weight loss maintained with every-other-week and monthly regimens, and up to 97% of weight loss maintained on every-other-week dosing.
analyst_ratingOppenheimer raised its price target on Viking Therapeutics to $120 from $100 and kept an Outperform rating on the shares.
analyst_ratingB.Riley reiterated a Buy rating and $85.00 price target on Viking Therapeutics following the release of the Phase 1 subcutaneous VK2735-102 maintenance trial data.